This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Personalized medicine is rapidly evolving in cancer theranostics, with technology now available that allows clinicians to optimize doses of radiopharmaceuticals on an individual patient level, according to experts. Kesner recently wrote an article about software applications in the field that was published in the Journal of Nuclear Medicine.
The use of somatostatin receptor PET imaging and therapy in meningiomas is on the rise, and new guidelines on their use can help pave the way to improved outcomes for patients, experts noted in a recent article. The article was published October 10 in the Journal of Nuclear Medicine. The full article is available here.
Reshaping the hospital's nuclear medicine and radiopharmaceutical strategy toward theranostics involves intensive and inclusive planning, Beyder explained at SNMMI. Underwood led the nuclear medicine and radiopharmaceutical therapy team within radiation safety at Mayo Clinic and directly supports the program in Rochester.
She has co-authored more than 200 articles, focusing on developing radiopharmaceuticals for oncological imaging and therapy, the society said. Aebersold Award for outstanding achievement for basic science research applied to nuclear medicine in 2020; and the Glenn T.
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
We hope you enjoy our article as well as the opportunity to hear directly from the recipients. Beyder played a key role in launching the radiopharmaceutical therapy (RPT) comprehensive center of excellence at WU, BJH, and Siteman Cancer Center last year. from Ukraine.
While recent evidence suggests that theranostic agents may be more effective when used earlier for prostate cancer patients, experts recommend proceeding conservatively with theranostic treatments until more is known about dose limits, according to an article published March 21 by the RSNA.
Evans, a professor in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco, was recognized for his work in biomarker discovery and radiopharmaceutical development. He has published more than 90 peer-reviewed articles and is a co-inventor on 13 patents pending or issued.
A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. asked Michael Morris, MD, of Memorial Sloan Kettering Cancer Center in New York for an article in the Journal of Nuclear Medicine (JNM) last year. Key to a good theranostics center Stay tuned for the next article in this series.
FLAIR WMH may have specific risk factors and pathologic underpinnings in [repetitive head impact] RHI-exposed individuals," Alosco's team concluded in their article published in December 2023 in Neurology. The work builds on previous research.
He has published more than 1,000 articles, is the author or co-author of 10 textbooks, and member of editorial boards for more than 35 journals. Beyder played a key role in launching the radiopharmaceutical therapy (RPT) comprehensive center of excellence at WU, BJH, and Siteman Cancer Center last year.
BWXT Medical will collaborate closely with NorthStar, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, to streamline production processes, enhance safety protocols and innovate new methods of isotope generation.
She has chaired the Advocacy Domain within SNMMI’s Value Initiative, the Committee on Government Relations, and the Committee on Radiopharmaceuticals and has participated in many other committees, such as the Committee on Ethics, the Women in Nuclear Medicine Committee, and the Scientific Program Committee.
As SNMMI president-elect, I plan to focus on bringing and integrating radiopharmaceutical theranostics into the clinic to benefit as many patients as possible," Urbain said in an SNMMI announcement. He has published approximately 100 journal articles and 15 book chapters and has given more than a thousand invited speaker presentations.
A member of the European Association of Nuclear Medicine, the Society of Radiopharmaceutical Sciences, and the American Chemical Association, Cutler holds 12 patents and has published 95 peer-reviewed journal articles and eight book chapters.
The article explores the theranostic applications of Terbium radionuclides, highlighting their diagnostic and therapeutic potential in nuclear medicine. The post Terbium Radionuclides for Theranostic Applications in Nuclear Medicine appeared first on Open MedScience.
This article examines the cancer risks associated with radionuclide administration in medical treatments and strategies for mitigation. The post Assessing the Cancer Risk in Patients Administered Radionuclides appeared first on Open MedScience.
As SNMMI president-elect, I plan to focus on bringing and integrating radiopharmaceutical theranostics into the clinic to benefit as many patients as possible. Urbain has published about 100 journal articles and 15 book chapters and has given more than a thousand invited speaker presentations.
This article reviews key Phase III clinical trials for ALSYMPCA, NETTER-1, and VISION therapies, highlighting advancements in cancer treatment. The post Clinical Trials: Advancements in ALSYMPCA, NETTER-1, and VISION Therapies appeared first on Open MedScience.
The major stumbling block in the clinical translation of TAT remains the development of a sturdy supply chain of these radionuclides that will match the clinical demand, IAEA scientists wrote in an article published March 11 in Nuclear Medicine and Biology. The full article is available here.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content